샘플 요청 목록

 카트 문의
시장보고서
상품코드
1777586

위암 치료 시장

Stomach Cancer Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 371 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 위암 치료 시장은 2030년까지 104억 달러에 도달

2024년에 52억 달러로 추정되는 세계의 위암 치료 시장은 2024-2030년의 분석 기간에 CAGR 12.1%로 성장하며, 2030년에는 104억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 표준화학요법은 CAGR 13.6%를 기록하며, 분석 기간 종료시에는 70억 달러에 달할 것으로 예측됩니다. 표적치료 부문의 성장률은 분석 기간 중 CAGR 9.2%로 추정됩니다.

미국 시장은 14억 달러로 추정, 중국은 CAGR 16.6%로 성장 예측

미국의 위암 치료 시장은 2024년에 14억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 22억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 16.6%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 8.7%와 10.9%로 예측됩니다. 유럽에서는 독일이 CAGR 약 9.7%로 성장할 것으로 예측됩니다.

세계의 위암 치료 시장 - 주요 동향과 촉진요인 정리

위암 치료가 전 세계에서 의료 시스템 전반에서 다시 주목받는 이유는 무엇인가?

위암은 여전히 전 세계 암 관련 사망의 주요 원인 중 하나이며, 특히 동아시아, 동유럽, 라틴아메리카 일부 지역에서는 여전히 주요 사망 원인 중 하나입니다. 식품 안전성 향상, 헬리코박터 파일로리균 제균, 조기 검진 등의 노력으로 일부 지역에서는 전체 발병률이 감소하고 있지만, 많은 국가에서는 진단이 늦고 치료 접근성이 제한되어 있으며, 여전히 큰 건강 문제로 남아 있습니다. 전 세계 의료계는 위암에 대한 의식의 향상, 검진 구상 확대, 데이터 수집 개선 등을 통해 위암의 진정한 부담을 강조하는 데 초점을 맞추었습니다. 일본, 한국, 중국 등 위험도가 높은 국가에서는 체계적인 검진 프로그램을 통해 치료 가능한 초기 단계에서 더 많은 사례를 발견하여 근본적인 외과적 치료와 약리학적 치료에 대한 수요가 급증하고 있습니다. 위암이 더 진행된 단계에서 발병하는 경향이 있는 유럽과 미국에서는 생존기간을 연장하고 삶의 질을 개선하는 새로운 전신요법에 대한 임상적 관심이 높아지고 있습니다. 이러한 새로운 초점은 전 세계에서 위암으로 인한 사망률을 관리하고 궁극적으로 감소시키기 위해 제약 기술 혁신, 의료 시스템 계획 및 학술연구를 보다 협력적이고 전략적인 노력으로 발전시켜 나가고 있습니다.

표적치료와 면역종양학은 어떻게 치료의 전망을 재정의하고 있는가?

위암 치료 상황은 정밀의료, 바이오마커 검사, 면역치료의 발전에 힘입어 큰 변화의 시기를 맞이하고 있습니다. 기존에는 수술, 화학요법, 방사선 치료로 치료하던 위암은 현재 분자 아형, 유전자 변이, PD-L1 발현 수준 등을 고려한 맞춤형 접근법으로 관리되고 있습니다. 트라스투주맙과 같은 HER2 표적치료제는 HER2 양성 위암 환자의 예후를 크게 개선시켰고, 새로운 항체약물접합체(ADC)와 티로신 키나아제 억제제는 다른 암 유발 인자에 대한 치료법을 확장하고 있습니다. 펨브롤리주맙이나 니볼루맙과 같은 면역관문억제제는 진행성 또는 전이성 위암 환자, 특히 미세 위성 불안정성(MSI-H)이 높거나 종양 돌연변이 부하(TMB)가 높은 환자에서 유망 결과를 보이고 있습니다. 면역요법과 화학요법 및 항혈관신생제와의 병용요법은 내성을 극복하고 반응 지속성을 개선하기 위해 검토되고 있습니다. 액체생검과 차세대 시퀀싱은 더 빠르고 정확한 치료법 선택을 용이하게 하여 위암 환자의 개인 맞춤형 치료의 시대를 열어가고 있습니다. 규제 당국의 승인이 가속화되고 임상시험 파이프라인이 강화됨에 따라 이러한 치료법의 발전은 1차 치료와 난치성 치료 모두에서 표준 치료를 크게 재편할 것으로 예측됩니다.

시장 수요는 어디에서 확대되고 있으며, 어떤 환자 집단이 치료 수요를 주도하고 있는가?

위암 치료에 대한 시장 수요는 전 세계에서 증가하고 있지만, 환자 부담이 가장 큰 곳은 중국, 일본, 한국 등 아시아태평양 국가로 전 세계 환자 수의 절반 이상을 차지하고 있습니다. 이들 지역은 적극적인 검진 정책, 강력한 정부 지원, 확립된 치료 프로토콜이 특징이며, 조기 개입과 의약품 판매 측면에서 핫스팟이 되고 있습니다. 미국, 독일, 영국 등 서유럽 국가에서는 위암의 발병률이 상대적으로 낮은 반면, 위암의 젊은 연령층으로의 이동과 높은 진행기 발병률로 인해 치료 수요가 증가하고 있습니다. 라틴아메리카, 동유럽, 아프리카 일부 지역에서는 유병률이 증가하고 있지만, 발견 지연, 치료 인프라, 약물 접근성 등의 문제에 직면해 있으며, 제네릭 화학요법제, 바이오시밀러, 공중보건 파트너십의 기회가 강조되고 있습니다. 신규 진단의 대부분을 차지하는 고령 환자들은 저독성, 내약성 요법에 대한 수요를 주도하고 있으며, 젊은 환자들은 가임력 보존 치료와 장기 생존 계획에 대한 관심을 높이고 있습니다. 도시화, 식습관의 변화, 개발도상국에서의 지속적인 헬리코박터 파일로리균 감염도 치료 대상 인구의 꾸준한 증가에 기여하고 있으며, 적시에 효과적이고 저렴한 치료를 제공하는 의료 시스템에 대한 압력을 가하고 있습니다.

세계 위암 치료 시장의 장기적인 성장 동력은?

위암 치료 시장의 성장은 인구 동향, 진화하는 치료 옵션, 정책적 프레임워크, 진단의 발전이 결합하여 이루어지고 있습니다. 장기적인 주요 요인은 전 세계 인구의 고령화, 위암의 기준선 위험 증가, 치료가 필요한 환자군의 확대입니다. 분자 프로파일링과 동반 진단의 발전으로 종양 전문의들은 "획일적인" 화학요법에서 특정 종양 생물학을 표적으로 하는 정밀 기반 요법으로 전환할 수 있게 되었으며, 이를 통해 효능을 높이고 부작용을 최소화할 수 있게 되었습니다. 암 면역치료의 세계가 확대되면서 진행성 질환이나 난치성 질환에 대한 새로운 치료의 길이 열리고 있습니다. 정부와 의료기관은 조기발견과 치료 접근성을 우선시하는 암 대책 프로그램에 투자하고 있으며, 제약사들은 특히 병용요법 및 차세대 생물제제에 대한 연구개발 투자 강화로 대응하고 있습니다. 이와 함께 신흥 시장에서는 종양학 인프라 구축과 의약품 상환 정책의 개혁이 진행되어 기존 치료법과 새로운 치료법에 대한 접근성이 확대되고 있습니다. 원격 종양학, 전자의무기록, 국제 공동 임상시험의 역할이 증가하면서 환자 관리와 데이터에 기반한 치료의 최적화가 강화되고 있습니다. 위암에 대한 과학적 이해가 깊어지고 치료법 혁신이 진행됨에 따라 위암 치료 시장은 세계에서 가장 공격적이고 진단이 어려운 악성 종양 중 하나에 대처하는 데 중요한 역할을 하는 것을 배경으로 지속적인 성장 태세를 보이고 있습니다.

부문

치료 유형(표준화학요법, 표적치료, 면역치료), 적응 질환(위암/위식도 접합부 암, 위장관 기질 종양), 투여 경로(경구제, 주사제)

조사 대상 기업의 예

  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • CELLTRION INC.
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • GSK plc
  • Harbour BioMed
  • Imugene Limited
  • Innovent Biologics, Inc.
  • Ipsen Pharma
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Mirxes
  • Mylan N.V.
  • Myriad Genetics, Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Samsung Bioepis
  • Sanofi S.A.
  • TAIHO PHARMACEUTICAL CO., LTD.
  • Teva Pharmaceutical Industries Ltd.
  • Triumvira Immunologics
  • WMT AG

AI 통합

당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.05

Global Stomach Cancer Treatment Market to Reach US$10.4 Billion by 2030

The global market for Stomach Cancer Treatment estimated at US$5.2 Billion in the year 2024, is expected to reach US$10.4 Billion by 2030, growing at a CAGR of 12.1% over the analysis period 2024-2030. Standard Chemotherapy, one of the segments analyzed in the report, is expected to record a 13.6% CAGR and reach US$7.0 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 16.6% CAGR

The Stomach Cancer Treatment market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 16.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.7% and 10.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.7% CAGR.

Global Stomach Cancer Treatment Market - Key Trends & Drivers Summarized

Why Is Stomach Cancer Treatment Receiving Renewed Global Focus Across Healthcare Systems?

Stomach cancer, or gastric cancer, remains one of the leading causes of cancer-related mortality worldwide, particularly in East Asia, Eastern Europe, and parts of Latin America. While overall incidence is declining in some regions due to improved food safety, Helicobacter pylori eradication, and early screening efforts, it continues to pose a significant health challenge due to late-stage diagnosis and limited treatment accessibility in many countries. The global healthcare community is shifting its focus toward stomach cancer due to rising awareness, expanded screening initiatives, and improvements in data collection that underscore the disease's true burden. In high-risk countries such as Japan, South Korea, and China, organized screening programs are detecting more cases at an earlier, potentially curable stage-driving a surge in demand for curative surgical and pharmacologic interventions. In the West, where stomach cancer tends to present at more advanced stages, there is growing clinical attention on novel systemic therapies that can extend survival and improve quality of life. This renewed focus is pushing pharmaceutical innovation, health system planning, and academic research into more coordinated, strategic efforts to manage and eventually reduce stomach cancer mortality on a global scale.

How Are Targeted Therapies and Immuno-Oncology Redefining the Treatment Landscape?

The stomach cancer treatment landscape is undergoing a major transformation fueled by advances in precision medicine, biomarker testing, and immunotherapy. Traditionally treated with surgery, chemotherapy, and radiation, stomach cancer is now being managed with more tailored approaches that consider molecular subtypes, genetic mutations, and PD-L1 expression levels. HER2-targeted therapies, such as trastuzumab, have significantly improved outcomes for patients with HER2-positive gastric cancer, while new antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors are expanding the arsenal against other oncogenic drivers. Immune checkpoint inhibitors like pembrolizumab and nivolumab have shown promising results in patients with advanced or metastatic gastric cancer, particularly in those with high microsatellite instability (MSI-H) or elevated tumor mutational burden (TMB). Combination therapies-pairing immunotherapy with chemotherapy or anti-angiogenic agents-are being explored to overcome resistance and improve response durability. Liquid biopsies and next-generation sequencing are facilitating earlier and more accurate treatment selection, ushering in an era of personalized care for stomach cancer patients. As regulatory approvals accelerate and clinical trial pipelines deepen, these therapeutic advances are expected to significantly reshape the standard of care in both first-line and refractory settings.

Where Is Market Demand Expanding, and Which Patient Populations Are Driving Treatment Needs?

Market demand for stomach cancer treatment is rising globally, with the highest patient burden concentrated in Asia-Pacific countries such as China, Japan, and South Korea, which account for over half of the world’s cases. These regions are characterized by proactive screening policies, strong government support, and well-established treatment protocols, making them hotspots for both early intervention and pharmaceutical sales. In Western countries, including the United States, Germany, and the UK, although incidence is comparatively lower, a shift toward younger-onset gastric cancer cases and high rates of advanced-stage presentation are intensifying treatment demands. Latin America, Eastern Europe, and parts of Africa are experiencing growing prevalence but face challenges related to late detection, treatment infrastructure, and drug access-highlighting opportunities for generic chemotherapy agents, biosimilars, and public health partnerships. Elderly patients, who account for a large proportion of new diagnoses, are driving demand for less toxic, more tolerable regimens, while younger patients are prompting interest in fertility-sparing treatments and long-term survivorship planning. Urbanization, dietary shifts, and persistent H. pylori infection in developing regions are also contributing to a steady expansion in the treatment-eligible population, creating pressure on healthcare systems to provide timely, effective, and affordable care.

What’s Driving the Long-term Growth of the Stomach Cancer Treatment Market Globally?

The growth in the stomach cancer treatment market is driven by a confluence of demographic trends, evolving therapeutic options, policy frameworks, and diagnostic advancements. A primary long-term driver is the aging global population, which is increasing the baseline risk for stomach cancer and expanding the pool of patients needing treatment. Advances in molecular profiling and companion diagnostics are enabling oncologists to move away from “one-size-fits-all” chemotherapy to precision-based regimens that target specific tumor biology-improving efficacy and minimizing side effects. The global expansion of cancer immunotherapy is opening new treatment windows for advanced or previously intractable cases. Governments and health organizations are investing in cancer control programs that prioritize early detection and access to care, while pharmaceutical companies are responding with intensified R&D investment, particularly in combination therapies and next-gen biologics. In parallel, emerging markets are building oncology infrastructure and reforming drug reimbursement policies, broadening access to both established and novel therapies. The increasing role of tele-oncology, electronic health records, and global clinical trial collaboration is also enhancing patient management and data-driven treatment optimization. As scientific understanding of gastric cancer deepens and therapeutic innovations continue to emerge, the stomach cancer treatment market is poised for sustained growth-anchored by its crucial role in addressing one of the world’s most aggressive and underdiagnosed malignancies.

SCOPE OF STUDY:

The report analyzes the Stomach Cancer Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Standard Chemotherapy, Targeted Therapy, Immunotherapy); Disease Indication (Gastric Cancer / Gastroesophageal Junction cancer, Gastrointestinal Stromal Tumors); Administration Route (Oral, Injectable)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • CELLTRION INC.
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • GSK plc
  • Harbour BioMed
  • Imugene Limited
  • Innovent Biologics, Inc.
  • Ipsen Pharma
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Mirxes
  • Mylan N.V.
  • Myriad Genetics, Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Samsung Bioepis
  • Sanofi S.A.
  • TAIHO PHARMACEUTICAL CO., LTD.
  • Teva Pharmaceutical Industries Ltd.
  • Triumvira Immunologics
  • WMT AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Stomach Cancer Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Gastric Cancer Throws the Spotlight on the Urgent Need for Targeted and Multimodal Treatment Approaches
    • Surge in Demand for Precision Oncology Spurs Growth in HER2-positive and MSI-high Targeted Therapies for Stomach Cancer
    • Here's How the Integration of Immunotherapy Expands the Addressable Market Beyond Traditional Chemotherapy Protocols
    • Advancements in Biomarker Testing and Genomic Profiling Strengthen the Business Case for Personalized Gastric Cancer Care
    • Here's the Story: Early-stage Diagnosis Rates Remain Low, Driving Innovation in Neoadjuvant and Adjuvant Treatment Strategies
    • Growing Pipeline of Immune Checkpoint Inhibitors and Anti-angiogenesis Agents Fuels Novel Treatment Combinations
    • Increased Adoption of Minimally Invasive Surgery and Robotic-assisted Resection Enhances Curative Outcomes in Eligible Patients
    • Expansion of Targeted Therapy Access in Emerging Markets Unlocks Commercial Opportunities for Biosimilars and Biologics
    • Growth of Tele-oncology and Remote Monitoring Tools Enhances Continuity of Gastric Cancer Treatment in Underserved Areas
    • Manufacturing Innovation and Cold Chain Optimization Sustain Global Supply of Injectable and Infusible Oncology Products
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Stomach Cancer Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Stomach Cancer Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Stomach Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Standard Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Standard Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Standard Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gastric Cancer / Gastroesophageal Junction cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gastric Cancer / Gastroesophageal Junction cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Gastric Cancer / Gastroesophageal Junction cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Gastrointestinal Stromal Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Gastrointestinal Stromal Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Gastrointestinal Stromal Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • JAPAN
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • CHINA
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • EUROPE
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Stomach Cancer Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Stomach Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • FRANCE
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • GERMANY
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Spain 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Russia 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Stomach Cancer Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 149: Australia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Australia Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Australia 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • INDIA
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 158: India Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: India Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: India 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 161: India Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 167: South Korea Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: South Korea Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: South Korea 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Asia-Pacific Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 185: Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 186: Latin America Historic Review for Stomach Cancer Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Latin America 15-Year Perspective for Stomach Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 197: Argentina Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Argentina Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Argentina 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 206: Brazil Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Brazil Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Brazil 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 215: Mexico Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Mexico Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Mexico 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Latin America Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Latin America 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 233: Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 234: Middle East Historic Review for Stomach Cancer Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Middle East 15-Year Perspective for Stomach Cancer Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 245: Iran Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Iran Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Iran 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 254: Israel Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Israel Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Israel 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Saudi Arabia Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Saudi Arabia 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 272: UAE Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: UAE Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: UAE 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Rest of Middle East Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Rest of Middle East 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • AFRICA
    • Stomach Cancer Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 290: Africa Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Africa Historic Review for Stomach Cancer Treatment by Treatment Type - Standard Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Africa 15-Year Perspective for Stomach Cancer Treatment by Treatment Type - Percentage Breakdown of Value Sales for Standard Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Stomach Cancer Treatment by Disease Indication - Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Stomach Cancer Treatment by Disease Indication - Percentage Breakdown of Value Sales for Gastric Cancer / Gastroesophageal Junction cancer and Gastrointestinal Stromal Tumors for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Stomach Cancer Treatment by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Stomach Cancer Treatment by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Stomach Cancer Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제